Bengaluru’s OneSource Pharma Eyes $ 500 M Revenue Amid License Cliff
Bengaluru-based OneSource Specialty Pharma, a CDMO demerged from Strides Pharma in 2024, is poised for quick development, projecting $ 500 million in earnings by FY 28 with 40 % EBITDA margins. This rise aligns with the coming close to expiration of semaglutide patents and the growing GLP- 1 market.
- Growth Vehicle drivers: The firm’s development is fueled by Drug-Device Mixes, particularly GLP- 1 injection pens.
- Capacity Growth: Considerable capital expenditure will boost cartridge capability to 220 million systems by FY 27, sustained by long-term agreements.
- Regulative Benefit: OneSource’s USFDA-approved Bengaluru center offers biologics fill-finish and gadget assembly abilities.
